"Employers doubled down on strategies to manage cost growth while finding ways to improve key benefits to support employees and their families in 2024, including expanded coverage for GLP-1 medications and fertility treatments," Ed Lehman, Mercer's U.S. health leader, said in a statement.

Tracy Watts, Mercer's national leader for U.S. health policy, said GLP-1s could "turn the tide on the obesity epidemic and positively impact downstream medical costs."

"Cost is clearly a concern, and employers are adding authorization requirements to ensure the medications are used by members who will benefit the most," Watts said.

Drug prices are among the biggest threats to healthcare affordability, according to 99% of the nearly 190 employers surveyed recently by the National Alliance of Healthcare Purchaser Coalitions.

In the NAHPC survey, about 46% of employers said they cover GLP-1s for obesity, and another 21% said they are debating doing so in the next three years. Of those companies either offering or considering GLP-1 coverage for obesity treatment, many said they might take steps to manage costs, such as limiting access to those with chronic conditions or a certain body-mass index.